News | February 08, 2022
GlaxoSmithKline Pharmaceuticals delivers strong financials in Q3FY22
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
Sun Pharma Advanced Research Company has reported standalone financial results for the period ended December 31, 2021
IOL Chemicals and Pharmaceuticals has reported standalone financial results for the period ended December 31, 2021
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India
The audit is a PAI for two of its product applications filed from this facility
In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21
Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA
Subscribe To Our Newsletter & Stay Updated
